Evommune, Inc.
Evommune, Inc. is listed today as Evommune, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2024 | $116 M | No. 4 | $50 to $250 million | equity | SEC | |
| Mar 2023 | $58 M | No. 3 | $50 to $250 million | equity | SEC | |
| Aug 2021 | $82 M | No. 2 | $50 to $250 million | equity | SEC | |
| Jun 2020 | $12 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Evommune, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2025).
SEC Form D · Jan 2025
The industry group it chose in its notices: Other.
SEC Form D · Jan 2025
That is all the official record says: Evommune, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Evommune, Inc. are on record.
Investors#
13 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| 7. Cooperative Ua Lsp | Person | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| David E. Cohen | Person | not stated | not stated | Held Series Seed preferred stock, director (Form 3, 2025) | SEC Form 3 |
| Eugene Bauer | Person | not stated | not stated | Held Series Seed and B preferred stock, director (Form 3, 2025) | SEC Form 3 |
| Janice Suzann Drew | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2025) | SEC Form 3 |
| Jeegar Pravinkumar Patel | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2025) | SEC Form 3 |
| Kyle Carver | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2025) | SEC Form 3 |
| Luis C. Pena | Person | not stated | not stated | Held Series Seed preferred stock, director (Form 3, 2025) | SEC Form 3 |
| Pivotal bioVenture Partners Fund I G.P., L.P. | Venture capital | not stated | not stated | Held Series Seed, A, B and C preferred stock, 10% owner, director (Form 3, 2025) | SEC Form 3 |
| Pivotal bioVenture Partners Fund I, L.P. | Venture capital | not stated | not stated | Held Series Seed, A, B and C preferred stock, 10% owner, director (Form 3, 2025) | SEC Form 3 |
| Pivotal bioVenture Partners Fund I U.G.P., Ltd | Venture capital | not stated | not stated | Held Series Seed, A, B and C preferred stock, 10% owner, director (Form 3, 2025) | SEC Form 3 |
| RA Capital Healthcare Fund LP | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner, director (Form 3, 2025) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner, director (Form 3, 2025) | SEC Form 3 |
| RA Capital Nexus Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, director (Form 3, 2025) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 25 investors.
Largest shareholders today
Institutions holding Evommune, Inc. shares, as of Sep 30, 2026.
- EQT Fund Management S.a r.l.$44 M12.79%
- Ra Capital Management, L.P.$29 M8.45%
- Point72 Asset Management, L.P.$20 M5.89%
- Pivotal bioVenture Partners Investment Advisor LLC$16 M4.66%
- Nan Fung Group Holdings Ltd$12 M3.48%
- Defilade Capital Management, L.P.$12 M3.46%
- Vestal Point Capital, LP$10 M3.02%
- Baker Bros. Advisors LP$10 M2.99%
- Kynam Capital Management, LP$10 M2.90%
- BlackRock, Inc.$10 M2.79%
- Vanguard Capital Management LLC$8 M2.43%
- Price T Rowe Associates Inc /MD/$7 M2.06%
- Millennium Management LLC$7 M2.05%
- American Century Companies Inc$6 M1.84%
- Qube Research & Technologies Ltd$6 M1.66%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Eugene Bauer | Executive officer | Jan 2025 |
| Gregory Moss | Executive officer | Jan 2025 |
| Janice Drew | Executive officer | Jan 2025 |
| Jeegar Patel | Executive officer | Jan 2025 |
| Kyle Carver | Executive officer | Jan 2025 |
| Luis Pena | Executive officer | Jan 2025 |
| Benjamin McGraw | Director | Jan 2025 |
| David Cohen | Director | Jan 2025 |
| Derek DiRocco | Director | Jan 2025 |
| Eugene Bauer | Director | Jan 2025 |
| Felice Verduyn-van Weegen | Director | Jan 2025 |
| Francois Beaubien | Director | Jan 2025 |
| Luis Pena | Director | Jan 2025 |
| Robert Hopfner | Director | Jan 2025 |
| Yuexin Yu | Director | Jan 2025 |
Went public since 2025. Its SEC number is that of a company listed on a stock exchange.